PART I . We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. ...
Q2 FY2026 — expected 2026-09-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001628280-26-017019 | EDGAR | 105K words |
| 2025-03-26 | 2024-12-31 | 0000950170-25-044775 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0000950170-24-036817 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0000950170-23-006838 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0001564590-22-010222 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001564590-21-014005 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001564590-20-009541 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-03 | 2025-09-30 | 0001628280-25-047919 | EDGAR | 63K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038594 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-071991 | EDGAR | — |
| 2024-11-04 | 2024-09-30 | 0000950170-24-120279 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0000950170-24-088951 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058192 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-059764 | EDGAR | — |
| 2023-08-04 | 2023-06-30 | 0000950170-23-038319 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019132 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-022893 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001564590-22-028299 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001564590-22-018698 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-17 | 0001628280-26-018397 | EDGAR | 5K words |
| 2026-03-12 | 0001628280-26-017018 | EDGAR | — |
| 2026-02-11 | 0001628280-26-007114 | EDGAR | — |
| 2026-01-13 | 0001628280-26-001955 | EDGAR | — |
| 2025-11-12 | 0001628280-25-051382 | EDGAR | — |
| 2025-11-10 | 0001628280-25-051168 | EDGAR | — |
| 2025-11-03 | 0001628280-25-047920 | EDGAR | — |
| 2025-09-02 | 0001357874-25-000005 | EDGAR | — |
| 2025-08-07 | 0001628280-25-038592 | EDGAR | — |
| 2025-08-06 | 0001628280-25-038094 | EDGAR | — |
165 total filings indexed. 136 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001357874 |
| Ticker | DTIL |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.precisionbiosciences.com |
| Listed | 2019-03-28 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report